Vol.

No.

May 18, 2018May 18, 2018

Free

DOWNLOAD THE PDF

Gynecology's deadly surprise: Cancers are frequently missed prior to routine procedures

Cover Story

Free

Gynecology's deadly surprise:

Cancers are frequently missed prior to routine procedures

By Matthew Bin Han Ong

As they reach for surgical tools, gynecologists vastly underestimate the probability that their patients have undiagnosed uterine cancers, a study by Yale University researchers found.

Conversation with The Cancer Letter Free

Vanderbilt's Alvarez: Gynecologists must properly assess all patients for cancer before surgery

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

OU's Mannel: Gynecologists must thoroughly evaluate postmenopausal women for hidden cancers

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Fox Chase's Rubin: Don't morcellate and you won't have to worry about cutting up missed cancers

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Yale's Desai: Gynecologists must preoperatively workup and discuss the risks, benefits, alternatives

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Olive: It's true, gynecologists don't biopsy masses as much as other surgeons

By Matthew Bin Han Ong

Free

Facing criticism from academic oncologists, Imbruvica's makers bring back low-dose pill

By Paul Goldberg

Clinical Free

ASCO publishes 5,800 abstracts

In Brief

Wui-Jin Koh named chief medical officer at NCCN

Park named to Vanderbilt-Ingram Cancer Center breast cancer leadership post

Richard Funnell to join WVU Cancer Institute

ASCO annual meeting merit awards

NCCN begins work on guidelines to improve cancer care in the Caribbean

Funding Opportunities

NETRF Announces grant funding for neuroendocrine cancer research

Colorectal Cancer Alliance announces up to $775,000 in available research funding

Clinical Roundup

FDA finds survival deficit in some patients taking Keytruda or Tecentriq as monotherapy in urothelial cancer with low expression of PD-L1

Tecentriq and Avastin plus carboplatin and paclitaxel show longer remissions vs. Avastin plus carboplatin and paclitaxel in metastatic NSCLC

Bone scan software calculates prognosis of advanced prostate cancer

Drugs & Targets

FDA approves first epoetin alfa biosimilar for the treatment of anemia

PREVIOUS ISSUE

NEXT ISSUE

Gynecology's deadly surprise:

Vanderbilt's Alvarez: Gynecologists must properly assess all patients for cancer before surgery

OU's Mannel: Gynecologists must thoroughly evaluate postmenopausal women for hidden cancers

Fox Chase's Rubin: Don't morcellate and you won't have to worry about cutting up missed cancers

Yale's Desai: Gynecologists must preoperatively workup and discuss the risks, benefits, alternatives

Olive: It's true, gynecologists don't biopsy masses as much as other surgeons

Facing criticism from academic oncologists, Imbruvica's makers bring back low-dose pill

ASCO publishes 5,800 abstracts

In Brief

Wui-Jin Koh named chief medical officer at NCCN

Park named to Vanderbilt-Ingram Cancer Center breast cancer leadership post

Richard Funnell to join WVU Cancer Institute

ASCO annual meeting merit awards

NCCN begins work on guidelines to improve cancer care in the Caribbean

Funding Opportunities

NETRF Announces grant funding for neuroendocrine cancer research

Colorectal Cancer Alliance announces up to $775,000 in available research funding

Clinical Roundup

FDA finds survival deficit in some patients taking Keytruda or Tecentriq as monotherapy in urothelial cancer with low expression of PD-L1

Tecentriq and Avastin plus carboplatin and paclitaxel show longer remissions vs. Avastin plus carboplatin and paclitaxel in metastatic NSCLC

Bone scan software calculates prognosis of advanced prostate cancer

Drugs & Targets

FDA approves first epoetin alfa biosimilar for the treatment of anemia

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login